Loading…
Loading…
SIGY does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for SIGY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for SIGY and 80,000+ other tickers.
See exactly how SIGY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for SIGY and 80,000+ other tickers.
Sigyn Therapeutics, Inc. operates as a therapeutic technology enterprise currently in its development phase. The company's core innovation is Sigyn Therapy, an advanced blood purification system designed to overcome the limitations of existing drugs and medical devices used to treat severe inflammatory disorders. A key focus is on sepsis, which represents a major cause of hospital-related deaths. Furthermore, Sigyn Therapeutics is actively evaluating the potential of Sigyn Therapy to address a broad spectrum of other therapeutic targets, including bacterial endotoxins, peptidoglycan, and…
The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc.
Sigyn Therapeutics (OTCMKTS:SIGY - Get Free Report) and Shuttle Pharmaceuticals (NASDAQ: SHPH - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends. Risk and Volatility Sigyn Therapeutics has a
Presentation on Tuesday, October 21st at 4:00 PM PT San Diego, California--(Newsfile Corp. - October 21, 2025) - Sigyn Therapeutics, Inc. (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, announced today that it will be presenting at the 19th annual Main Event on Tuesday, October 21st at 4:00 PM PT at the Hotel del Coronado in San Diego, California. Jim Joyce, CEO and Inventor will be giving the presentation.
Presentation on Tuesday, October 21st at 4:00 PM PT San Diego, California--(Newsfile Corp. - October 17, 2025) - Sigyn Therapeutics, Inc. (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, announced today that it will be presenting at the 19th annual Main Event on Tuesday, October 21st at 4:00 PM PT at the Hotel del Coronado in San Diego, California. Jim Joyce, CEO and Inventor will be giving the presentation.
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com